Key Highlights
- Second-quarter net Revenue was $64 million, down 35% from $99 million a year earlier, and the company swung to a net loss of $15 million.
- Gross Margin declined to 69% from 81%, and adjusted EBITDA turned negative.
- Surgical products grew 15%, but the wound-care Business declined 61% due to Medicare reimbursement changes effective January 1, 2026.
- The company reiterated full-year 2026 net-sales guidance of $260 million to $290 million with adjusted EBITDA approaching breakeven.
MiMedx Group (NASDAQ:MDXG), a maker of regenerative-medicine products derived from placental tissue, is grappling with a major Medicare reimbursement change that has sharply reduced its wound-care revenue, even as its surgical business continues to grow. The company's near-term outlook must be weighed against this significant headwind.
MiMedx develops and markets products using amniotic and placental tissue for wound care, surgical and other applications. Its business has historically been anchored in wound care, but a change in Medicare reimbursement effective at the start of 2026 has materially altered the Economics of that segment, while its surgical products, used in procedures such as certain reconstructive surgeries, have continued to grow.
Latest Developments
In its second-quarter 2026 results, MiMedx reported net revenue of $64 million, down 35% from $99 million a year earlier, and swung to a net loss of $15 million from prior-year net income, with adjusted EBITDA turning negative. Gross margin declined to 69% from 81%. The divergence within the business was stark: its surgical products grew 15%, but its wound-care business declined 61% due to Medicare reimbursement changes effective January 1, 2026, which introduced tighter coverage parameters and lower reimbursement in certain categories. The company reiterated full-year 2026 net-sales guidance of $260 million to $290 million with adjusted EBITDA approaching breakeven.
Financial and Business Position
MiMedx's results are dominated by the Medicare reimbursement change, which has severely pressured its wound-care revenue and swung the company to a loss, even as its surgical business grows. The reiterated guidance implies management expects some stabilization, but the magnitude of the wound-care decline underscores how exposed the company is to reimbursement policy. The growth in surgical products is a positive, and the company's placental-tissue technology addresses real clinical needs, but navigating the reimbursement headwind is the central challenge.
Stock-Market Context
The company carries a strong-buy analyst rating, an optimistic stance that contrasts with the sharp revenue decline and swing to a loss. A more constructive outcome would require the wound-care business to stabilize under the new reimbursement regime, the surgical business to keep growing, and profitability to recover toward the guided breakeven; the cautionary case is that the reimbursement change has materially impaired a core business, and that reimbursement policy remains a significant and largely uncontrollable risk.
What Investors Should Watch
Investors may focus on whether the wound-care business stabilizes under the new Medicare reimbursement parameters, continued growth in surgical products, gross-margin and adjusted-EBITDA trends against the reiterated guidance, any further reimbursement developments, and the company's cash generation. Evidence that MiMedx can stabilize its wound-care revenue while growing its surgical business and returning toward profitability would be needed to support a more constructive view.
MiMedx illustrates how a change in government reimbursement policy can rapidly and dramatically reshape the economics of a healthcare company, since the Medicare reimbursement change that took effect at the start of 2026 introduced tighter coverage and lower reimbursement that caused the company's wound-care revenue to fall sharply and swung the overall business to a loss. This exposure to reimbursement policy is a defining risk for companies like MiMedx that depend heavily on government payors, and it is largely outside the company's control. The more encouraging element is the growth in its surgical products, which provides a partial offset and a potential foundation for a more diversified business over time.






Please wait processing your request...